Adalimumab (Humira) is the most expensive drug in the world in terms of total sales: $19.9 billion in 2018. Five biosimilars (generic equivalents) have been approved by the FDA, but none have been marketed because they have been locked up in patent disputes by the manufacturer, Abbvie. The story is much...
Read More »

There are some questions in healthcare that can’t be answered with a randomized controlled trial. We can’t randomize babies to inhale secondary tobacco smoke or not to test its health effects. We can’t randomize people to different number of hours sitting the ER before receiving antibiotics after the decision is made...
Read More »